→
Investors should consider the company's solid growth metrics alongside recent challenges in the competitive landscape.
Amgen Inc has a market capitalization of $236.91B and is currently priced at $437.10, reflecting a decline of 1.60% from the previous close of $444.20. The company has a P/E ratio of 30.72 and an impressive EPS growth year-over-year of 88.23%, while revenue has grown by 9.95% in the same period. The stock's 52-week high is $447.03, and the 52-week low is $269.75, indicating volatility within the year.
Some investors view Amgen's 88.23% EPS growth year-over-year as a strong indicator of its profitability potential. Additionally, the company has maintained a robust revenue growth rate of 9.95%, which could suggest resilience in its market performance.
Conversely, Amgen’s P/E ratio of 30.72 may indicate that the stock is priced high relative to its earnings, raising concerns about potential overvaluation. Moreover, recent news of a failed Phase III study for a competing drug may weigh on investor sentiment.
Want AI analysis of your entire portfolio?
Helm Terminal connects to your brokerage, analyzes every holding, and delivers actionable intelligence weekly. Free to start.
Get started freeHelm provides financial data for informational purposes only. This is not financial, investment, or tax advice. Consult a qualified professional before making financial decisions.
Watch my tickers
Get an email when something changes on your tickers: the exact quote, dated and sourced. No account, no brokerage connection, unsubscribe anytime.
Amgen Inc has a market capitalization of $236.91B and is currently priced at $437.10, reflecting a decline of 1.60% from the previous close of $444.20. The company has a P/E ratio of 30.72 and an impressive EPS growth year-over-year of 88.23%, while revenue has grown by 9.95% in the same period. The stock's 52-week high is $447.03, and the 52-week low is $269.75, indicating volatility within the year.
Conversely, Amgen’s P/E ratio of 30.72 may indicate that the stock is priced high relative to its earnings, raising concerns about potential overvaluation. Moreover, recent news of a failed Phase III study for a competing drug may weigh on investor sentiment.
Some investors view Amgen's 88.23% EPS growth year-over-year as a strong indicator of its profitability potential. Additionally, the company has maintained a robust revenue growth rate of 9.95%, which could suggest resilience in its market performance.
Some investors view Amgen's 88.23% EPS growth year-over-year as a strong indicator of its profitability potential. Additionally, the company has maintained a robust revenue growth rate of 9.95%, which could suggest resilience in its market performance. Conversely, Amgen’s P/E ratio of 30.72 may indicate that the stock is priced high relative to its earnings, raising concerns about potential overvaluation. Moreover, recent news of a failed Phase III study for a competing drug may weigh on investor sentiment.
Amgen Inc has a market capitalization of $236.91B and is currently priced at $437.10, reflecting a decline of 1.60% from the previous close of $444.20. The company has a P/E ratio of 30.72 and an impressive EPS growth year-over-year of 88.23%, while revenue has grown by 9.95% in the same period. The stock's 52-week high is $447.03, and the 52-week low is $269.75, indicating volatility within the year.
Helm's analysis is generated by an AI model from live market data. It identifies risk signals, opportunities, and key metrics based on current fundamentals, recent price action, and analyst consensus. It does not execute trades, issue certified investment advice, or predict future prices.
Not financial advice. Informational use only. AI-generated content may contain errors. Consult a licensed financial advisor before making investment decisions. Helm Terminal is not registered as an investment advisor.
Helm Terminal offers free AI-powered stock analysis for AMGN at helmterminal.dev/analyze/AMGN, updated continuously during US market hours. No signup required.